-
NMPA Announcement on Matters Related to the Implementation of the 2025 Edition of the Pharmacopoeia of the People's Republic of China (No. 32, 2025)
2025-06-11
The 2025 Edition of the Pharmacopoeia of the People's Republic of China (hereinafter referred to as the Chinese Pharmacopoeia) has been issued by Announcement No. 29, 2025 of the National Medical Products Administration and the National Health Commission and shall come into force as of October 01, 2025.
-
Zolbetuximab for Injection Approved for Marketing by China NMPA
2025-06-11
Recently, the Zolbetuximab for Injection (trade name: 威络益/VYLOY) of Astellas Pharma Europe B.V. is approved for marketing by China NMPA.
-
Tagitanlimab Injection Approved for Marketing by China NMPA
2025-06-11
Recently, the Tagoliticimab Injection (trade name: 科泰莱) of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is approved for marketing by China NMPA.
-
Amimestrocel Injection Approved with Conditions for Marketing by China NMPA
2025-06-11
Recently, the Amimestrocel Injection (trade name: 睿铂生) of Platinumlife Biotechnology (Beijing) Co., Ltd. is approved with conditions through the priority review and approval procedure by China NMPA.
-
Innovative TCM Xiao’er Huangjin Zhike Granules Approved for Marketing by China NMPA
2025-06-11
Recently, the Class 1.1 innovative traditional Chinese medicine (TCM) Xiao' er Huangjin Zhike Granules of Beijing Dongfang Yunjia Pharmaceutical Co., Ltd. is approved for marketing through the priority review and approval procedure by China NMPA.
-
Recaticimab for Injection Approved for Marketing by China NMPA
2025-06-11
Recently, the Recaticimab for Injection (trade name: 艾心安) of Guangdong Hengrui Pharmaceutical Co., Ltd. is approved for marketing by China NMPA.
